Paper Chase is a research database designed to offer abstracts of research articles published in journals that have a highly rated impact factor as determined by ISI Impact Factor and PageRank. Abstracts are organized by date, with the most recently published papers listed first. 

Paper Chase

41.

WHO's new HIV guidelines: opportunities and challenges.

Lancet.
Mayer K, Beyrer C.
| Jul 27, 2013
42.

Karyomegalic interstitial nephritis.

Lancet.
Zschiedrich S, Huber TB, Hildebrandt F, Mihatsch MJ, Wiech T.
| Dec 21, 2013
43.

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

Lancet.
Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ.
| Jul 6, 2013
44.

First-line treatment of indolent lymphoma: axing CHOP?

Lancet.
Jacobson CA, Freedman AS.
| Apr 6, 2013
45.

Metchnikoff and the microbiome.

Lancet.
Podolsky SH.
| Nov 24, 2012
46.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Lancet.
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG, Samonigg H.
| Jan 26, 2013
47.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

Lancet.
Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS.
| Dec 8, 2012
48.

Ventricular arrhythmias and sudden cardiac death.

Lancet.
John RM, Tedrow UB, Koplan BA, Albert CM, Epstein LM, Sweeney MO, Miller AL, Michaud GF, Stevenson WG.
| Oct 27, 2012
49.

Postoperative radiation for prostate cancer.

Lancet.
Efstathiou JA.
| Dec 8, 2012
50.

Health-care reforms in the USA and England: areas for useful learning.

Lancet.
Blumenthal D, Dixon J.
| Oct 13, 2012
51.

EXAMINATION of new drug-eluting stents--top of the class!

Lancet.
Bhatt DL.
| Oct 27, 2012
52.

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Lancet.
Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ, Zucchiatti N.
| Oct 20, 2012
53.

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.

Lancet.
Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA.
| Oct 13, 2012
54.

How much CABG is good for us?

Lancet.
Jones DS.
| Aug 11, 2012
55.

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

Lancet.
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ.
| Aug 11, 2012
57.

Comprehensive clinical care for men who have sex with men: an integrated approach.

Lancet.
Mayer KH, Bekker LG, Stall R, Grulich AE, Colfax G, Lama JR.
| Jul 28, 2012
58.

Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy.

Lancet.
Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, Alkandari JR.
| Jul 21, 2012
59.

Cholera.

Lancet.
Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB.
| Jun 30, 2012
60.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Lancet.
Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK, Akil B.
| Jun 30, 2012